
礼来公司的畅销减肥针剂Zepbound(替尔泊肽)在一项新研究中帮助12岁及以上儿童安全减重,增强了这家药企进军年轻患者市场的努力。
Lilly & Co.’s blockbuster obesity shot Zepbound helped children aged 12 and older safely lose weight in a new study, bolstering the drugmaker’s efforts to break into the market for younger patients.
根据周日在“肥胖周”会议上公布的研究,这些患有肥胖或超重并伴有糖尿病前期、睡眠呼吸暂停等疾病的青少年,在服药一年半后,体重指数平均下降约18.5%。这项涉及160名患者(平均体重240磅)的试验发现,接受化学名为替尔泊肽的药物治疗者平均减重约40磅。
The adolescents, who were obese or overweight with conditions like pre-diabetes and sleep apnea, reduced their body mass index by an average of about 18.5% after taking the drug for a year and a half, according to the study presented at ObesityWeek on Sunday. The trial of 160 patients, with an average weight of 240 pounds, found those given the drug known chemically as tirzepatide lost an average of about 40 pounds.
据美国疾病控制与预防中心称,约五分之一儿童面临儿童肥胖问题。若Zepbound获批用于年轻患者,将成为帮助他们控制体重的又一工具。
About one in five children face childhood obesity, according to the US Centers for Disease Control and Prevention. Approval of Zepbound for younger patients would be another tool to help them control their weight.
在诺和诺德的减肥药Wegovy和Saxenda此前已在美国和欧洲获批用于12岁及以上儿童后,礼来在原本占据主导地位的数十亿美元肥胖药市场的青少年细分领域正在追赶。尽管如此,儿童肥胖率持续攀升,医疗专业人士和家长都在推动更多治疗选择。
Lilly is playing catch up in the adolescent segment of the multibillion-dollar obesity market it otherwise dominates, after Novo Nordisk S/A’s obesity drugs Wegovy and Saxenda previously won US and European approval for children 12 and older. Still, childhood obesity rates continue to climb, and medical professionals and parents alike are pushing for more treatment options.
明尼苏达大学儿科教授、发表于《美国医学会杂志》该研究的通讯作者Aaron Kelly表示,他认为Zepbound的获批范围“极有可能”会扩大至青少年群体。
Aaron Kelly, a professor of pediatrics at the University of Minnesota and the corresponding author of the study published in the Journal of the American Medical Association, said he believes it is “highly likely” Zepbound’s approval will be expanded to include adolescents.

Kelly说:“我们有责任研究并了解其在儿童群体中的安全性和有效性,以便让医疗服务提供者有信心开具处方。”
“It is incumbent upon us to research and understand the safety and efficacy in the pediatric population to give healthcare providers confidence in prescribing,” Kelly said.
这项研究在30多家医学研究中心进行,历时近三年,纳入12至18岁儿童。他们经历的副作用与服药成年人相似,恶心、呕吐等胃肠道问题是最常见的不良反应。
The study was conducted in over 30 medical research centers over the span of almost three years, and included children from the ages of 12 to 18. They experienced similar side effects as adults on the medication, with gastrointestinal issues like nausea and vomiting being the most frequently reported.
凯利表示,尽管这些发现可能无法推广到患有2型糖尿病的青少年或不被视为肥胖的青少年,但研究药物及其他影响其健康因素(包括饮食习惯以及心脏和代谢问题风险)的影响非常重要。他对最新结果有助于扩大儿童肥胖治疗选择持乐观态度。
Kelly said while the findings may not be generalizable to adolescents with type 2 diabetes or those not considered obese, it’s important to study the effects of medicines and other factors that influence their health, including eating habits and risks for heart and metabolic issues. He’s optimistic the latest results will help expand the treatment options for childhood obesity.
“我们必须认识到,某些患者能从这种疗法中获益良多,且获益远大于风险,”他说。
“We must recognize that certain patients can benefit greatly from this type of therapy and that the benefits greatly outweigh the risks,” he said.